Plasma leptin, hTERT gene expression, and anthropometric measures in obese and non-obese women with breast cancer

Breast Cancer: Basic and Clinical Research

Volumn 5, Issue 1, 2011, Pages 27-35

  Rahmati Yamchi, Mohammad ^a   Zarghami, Nosratallah ^a,b,c   Rahbani, Mohammad ^a   Montazeri, Ali ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

^c Cancer Research Network   (Iran)

Author keywords

Adipokienes; Breast cancer; Obesity

Indexed keywords

LEPTIN; MESSENGER RNA; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBESITY; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

EID: 79952974380     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S6734     Document Type: Article

References (36)

1. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006, CA. Cancer J Clin. 2006;56:168-83.
2. Bray F, McCarron P, Parkin D. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6:229-39.
3. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin. 2002;52:23-47.
4. Velie EM, Nechuta S, Osuch JR. Lifetime reproductive and anthropometric risk factors for breast cancer in ostmenopausal women. Breast Dis. 2005; 24:17-35.
5. Olsson A. Body mass index and breast cancer survival in relation to the introduction of mammographic screening. EJSO. 2009;1-7.
6. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med. 1997;216:28-43.
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348:1625-38.
8. Berclaz G, Li S, Price KN, Coates AS, Castiglione-Gertsch M, Rudenstam CM, et al. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15:875-84.
9. Tworoger SS, Heather Eliassen A, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocr Metab. 2007;92:1510-6.
10. Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer. 2007;14:669-77.
11. Meyerson M. Role of telomerase in normal and cancer cells. J Clinical Oncology. 2000;13:2626-34.
12. Paraskevi K, Sophia P, Stavros H. Structure and function of telomeres/ telomerase and their role in preleukaemia and haematologic malignancies. Haema. 2003;6(1):35-47.
13. Kumaki F, Kawai T, Hiroi S, Shinomiya N, Ozeki Y, Ferrans VJ, et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol. 2001;32:188-95.
14. Dumont N, Crawford YG, Sigaroudinia M, Nagrani SS, Wilson MB, Buehring GC, et al. Human mammary cancer progression model recapitulates methylation events associated with breast premalignancy. Breast Cancer Res. 2009;11(6):R87.
15. Mokbel KM, Parris CN, Ghilchik M, Amerasinghe CN, Newbold RF. Telomerase and lymph vascular invasion in breast cancer. Eur J Surg Oncol. 2000;126:30-3.
16. Mokbel KM, Parris CN, Ghilchik M. The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer. Am J Surg. 1999;178:69-72.
17. Elkak A, Meligonis G, Salhab M, Mitchell B, Blake J, Newbold R, et al. hTERT protein expression is independent of clinicopathological parameters and c-Myc protein expression in human breast cancer. J Carcinogenesis. 2005;4:17.
18. Zarghami N, Mohajeri A, Rahmati M. Prostate Specific Antigen Gene Expression and Telomerase Activity in Breast Cancer Patients: Possible Relationship to Steroid Hormone Receptors. Pharm-Sci. 2007.
19. Shay JW. Telomerase and cancer, Molecular Pathology of Early Cancer. Edited by Srivastava S, Hensen DE, Gazdar A. Washington, DC. IOS Press. 1999;405-24.
20. World Health Organization Obesity: preventing and managing the global epidemic report of a WHO consultation, World Health Organ Tech. Rep Ser. 2000;89:1-253.
21. Yi X, White DM, Aisner DL, Baur JA, Wright W, Shay JW. An alternate splicing variant of the telomerase catalytic subunit inhibits telomerase activity. Neoplasia. 2000;2:433-40.
22. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERT a splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia. 2000;2:426-32.
23. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obese Rev. 2003;4:157-73.
24. Potischman N, Swanson CA, Siiteri P, Hoover RN. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. Journal of National Cancer Institute. 1996;88:756-8.
25. Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE, et al. Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J. 2005;118:1507-16.
26. Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev. 2007;28:763-77.
27. Jarde T, Caldefie-Chézet F, Goncalves-Mendes N, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer. 2009;16:1197-210.
28. Roberta F, Mario G, Claudio P, Renato F, Giuseppe P, Laura F, et al. Cellular and molecular crosstalk between leptin receptor and estrogen receptor in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer. 2010;17:373-82.
29. Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat. 2004;86:191-6.
30. Wang L, Lim E, Toborek M, Hennig B. The role of fatty acids and caveolin-1 in tumor necrosis factor a-inducedvendothelialvcellvactivation. Metabolism Clin Exptl. 2008;57:1328-39.
31. Ren H, Zhao T, Wang X, et al. Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochem Biophys Res Commun. 2010;394(1):59-63.
32. Nikolaos S, Vassilis P, Yoichi F, Yusuke N, Aspasia T. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer. 2010;10:442.
33. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009;100: 578-82.
34. Kirkpatrick KL, Ogunkolade W, Elkak AE, Bustin S, Jenkins P, Ghilchick M, et al. hTERT expression in human breast cancer and non-cancerous breast tissue: correlation with tumour stage and c-Myc expression. Breast Cancer Res Treat. 2003;77:277-84.
35. Li H, Diao TY, Zhou ZY, Yang FY, Ma Q, Li QH. Relationship between the expression of hTERT and EYA4 mRNA in peripheral blood mononuclear cells with the progressive stages of carcinogenesis of the esophagus. J Experimental and Clinical Cancer Research. 2009;28:145.
36. Elkak A, Mokbel RC, Wilson C, Jiang W, Newbold R, Mokbel K. hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer. Anticancer Research. 2006;26:4901-4.